2005-000444-84: An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson\'s disease suffering from treatment-associated dyskinesia |
|
|
| | 3 | 53 | Europe | Sarizotan hydrocholride, EMD128130, | Merck KGaA, MERCK S.P.A. | Treatment-Associated Dyskinesia in Parkinson\'s Disease | | | | |